REVIEW EPIDEMIOLOGY 236
|
|
- Jesse Perkins
- 6 years ago
- Views:
Transcription
1 ACUTE CORONARY SYNDROME: THE COMMUNITY PHARMACISTS ROLE IN THE CONTINUUM OF CARE William E. Dager, PharmD * ABSTRACT Acute coronary syndrome describes a broad range of symptoms caused by myocardial ischemia and is a potentially life-threatening manifestation of coronary artery disease. The most recent update to the American College of Cardiology/American Heart Association guidelines for non ST-elevation myocardial infarction and unstable angina was published in The update highlights early risk stratification; new indications for pursuing an early invasive strategy; the early use of aspirin, clopidogrel, and lipid-lowering therapy; the use of glycoprotein IIb/IIIa inhibitors; and the use of anticoagulants. Long-term outcomes will depend on medications used after patients leave the hospital, making it imperative for the community pharmacist to play an active role in encouraging adherence to their complex medication regimens. (Adv Stud Pharm. 2007;4(9): ) Acute coronary syndrome (ACS) is an umbrella term describing a group of symptoms caused by acute myocardial ischemia that results from insufficient blood flow to the heart muscle. Upon presentation, patients with symptoms of ACS are typically classified by the *Pharmacist Specialist, University of California-Davis Medical Center, Sacramento, California. Address correspondence to: William E. Dager, PharmD, Pharmacist Specialist, University of California-Davis Medical Center, 2315 Stockton Boulevard, Sacramento, CA william.dager@ucdmc.ucdavis.edu. absence or presence of ST-segment elevation on a 12-lead electrocardiogram (ECG), as well as abnormal elevations of certain cardiac enzymes. Based on these criteria, patients are classified into 1 of 3 categories (Figure): Unstable angina (UA) Non ST-elevation myocardial infarction (NSTEMI; previously referred to as non Qwave myocardial infarction [MI]) STEMI (previously referred to as Q-wave MI) EPIDEMIOLOGY Acute coronary syndromes represent a significant public health burden. According to the American Heart Association (AHA), preliminary estimates indicate that approximately 1.6 million patients were hospitalized for ACS in 2004, including patients diagnosed with MI and with UA. Approximately of these patients were discharged with both diagnoses. 1 UA/NSTEMI is the more common diagnosis, with only 30% to 45% of patients with MI diagnosed with acute STEMI. 2 On a global scale, MI may be responsible for 40% to 50% of all mortality related to cardiovascular disease. 3 Recent data show that 25% of men and 38% of women will die within 1 year of having an initial recognized MI, 1 and reported 6-month mortality (including sudden death) among patients with UA ranged from 8% to 13%. 4,5 At age 40 or older, approximately 18% of men and 23% of women will die within 1 year following a first MI. The risk of recurrent MI, stroke, development of heart failure, or sudden death is also substantial in these patients. 1 More women than men present with STEMI, whereas more men than women will be diagnosed with NSTEMI. Women with STEMI tend to have a worse outcome than men with 236 Vol. 4, No. 9 October 2007
2 Figure. Stratification of ACS No ST-segment elevation Markers of myocardial necrosis not elevated Unstable angina Placque disruption or erosion Thrombus formation with or without embolization Oxygen supply to myocardial cells does not meet demand Active cardiac ischemia Elevated markers of myocardial necrosis NSTEMI (Q waves usually absent) ACS ST-segment elevation Elevated markers of myocardial necrosis STEMI (Q waves usually present) ACS = acute coronary syndrome; NSTEMI = non ST-segment elevation myocardial infarction; STEMI = STsegment elevation myocardial infarction. (ACC)/AHA Guidelines Registry observed an even higher in-hospital mortality rate (4.5%) compared with less than 2% reported in other ACS trials. 9 The prevalence of ACS also increases with age. Approximately 83% of patients who die from coronary artery disease were 65 or older. 1 In the Global Use of Strategies to Open Occluded Coronary Arteries IIb study of coronary vascular occlusion, the median age for those with acute STEMI was 63 years, whereas that for patients with NSTEMI was 66 years. 12 Predictions for the year 2020 and beyond suggest that ischemic heart disease will be the leading cause of death and disability worldwide. 13 ACS is likely to remain a leading cause of hospitalization, both as a result of the aging population and also because of a growth in risk factors for coronary heart disease (CHD; eg, diabetes and obesity), and will continue to present a major healthcare challenge in the foreseeable future. 9 STEMI. Women appear to have better outcomes with UA, however, no gender differences in outcomes have been observed in NSTEMI. 6,7 Persistent ST-segment elevation accompanied by chest pain usually indicates total coronary occlusion, leading to irreversible myocardial damage that requires immediate reperfusion of the affected coronary artery. 8 Approximately 33% of patients with STEMI die within 24 hours of the onset of ischemia, and many of the survivors suffer significant morbidity. 8 Like STEMI, UA and NSTEMI are potentially life-threatening and are major causes of emergency medical care and hospitalization. 9,10 Among patients with UA or NSTEMI, approximately 15% will die or have a reinfarction within 30 days of diagnosis, 11 and approximately 30% of patients with UA will have an MI within 3 months. 4 Early data from the Can Rapid Risk Stratification of UA Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology FINANCIAL BURDEN OF ACS Acute coronary syndrome exacts a high toll in terms of direct, treatment-related, and management costs, as well as indirect, social, and economic costs. 14,15 Direct US costs in 2007 for CHD most of which consist of ACS, physician, and other professional costs are estimated at $83.6 billion. These include hospital costs ($48.4 billion), nursing home costs ($11.6 billion), the cost of drugs and other medical durables ($9.2 billion), physicians/other professionals ($12.5 billion), and home healthcare at $1.9 billion bring the estimated total to $75.2 billion. 16 Indirect US costs of CHD for 2006 (because of lost productivity) are estimated to be $68 billion. 16 PATHOPHYSIOLOGY The myocardial ischemia associated with ACS is most often a result of rupture or erosion of atherosclerotic plaque within the coronary arteries. This disrup- University of Tennessee Advanced Studies in Pharmacy 237
3 tion results in exposure of thrombogenic elements within the plaque on which platelets aggregate and a thrombus subsequently forms. This thrombus limits perfusion of blood beyond the disrupted plaque, thus reducing myocardial oxygen supply and causes myocardial ischemia. The extent and duration of coronary artery occlusion by the thrombus is an important determinant of whether a patient develops UA, NSTEMI, or STEMI. In general, more complete thrombotic occlusion results in greater myocardial injury. STEMI is often associated with complete occlusion of the infarct-related coronary artery, resulting in the characteristic ECG changes and release of biomarkers of myocardial injury (eg, troponin) into the blood. UA and NSTEMI are closely related and differ only in whether the myocardial ischemia is severe enough to produce sufficient myocardial damage to release these biomarkers. If no biomarker is detectable in the blood, then the patient with ACS is considered to have UA whereas NSTEMI is associated with elevated biomarkers. DIAGNOSIS Symptoms of ACS may, but do not always, include chest pain or pressure, referred pain, nausea, vomiting, dyspnea, diaphoresis, and lightheadedness. Some patients may present without chest pain; in 1 study, 17 sudden dyspnea was the sole presenting feature in 4% to 14% of patients with acute MI. Pain may be referred to the arm, the jaw, the neck, the back, or even the abdomen. Pain radiating to the shoulder, left arm, or both arms somewhat increases the likelihood of ACS (Table). 11,18 Although atypical symptoms do not necessarily rule out ACS, a combination of atypical symptoms improves identification of low-risk patients. 19 Typically, UA presents as chest pain or equivalent ischemic discomfort with at least 1 of 3 features 20 : Pain occurs at rest (or with minimal exertion), usually lasting more than 10 minutes Pain is severe and of new onset (ie, within the prior 4 6 weeks) Pain occurs with a crescendo pattern (ie, distinctly more severe, prolonged, or frequent than previously) Unstable angina and NSTEMI often present in a similar manner, and the distinction is often made hours or days later, when the results of cardiac biomarker analysis become available. 21 A diagnosis of NSTEMI is not established until elevated cardiac biomarkers evidence of myocardial necrosis are detected in a patient with the clinical features of UA. 1 The 3 important clinical biomarkers crucial for distinguishing NSTEMI from UA include creatine kinase (CK), the more specific isoenzyme CK-MB, and 2 cardiac troponins, troponin T and troponin I. The ACC/AHA guidelines recommend the use of cardiac troponins as the preferred biomarker for confirming a diagnosis of MI. 11 Although the ECG may be completely normal in a patient with myocardial Table. Potential Features of ACS Based on Clinical Features Symptoms History Physical examination ECG Cardiac biomarkers High Likelihood Intermediate Likelihood Low Likelihood Chest or left arm pain or discomfort reproducing previously documented angina Known history of CAD or MI Transient mitral regurgitation, hypotension, diaphoresis, or rales New transient ST-segment deviation or T-wave inversions with symptoms Elevated cardiac-specific troponin level or elevated CK-MB isoenzyme levels Chest or left arm pain or discomfort Patient aged >70 years, male, or diabetes mellitus Manifestations of extracardiac vascular disease Q waves; abnormal ST-segment or T waves not documented to be new Cardiac biomarker levels may or may not be elevated Symptoms with features other than those indicating intermediate or high likelihood Recent cocaine use Chest pain reproduced by palpation Normal ECG Cardiac biomarker levels not elevated ACS = acute coronary syndrome; CAD = coronary artery disease; CK-MB = creatine kinase-mb; ECG = electrocardiogram; MI = myocardial infarction. Data from Anderson et al Vol. 4, No. 9 October 2007
4 ischemia and evolving infarction, ST-elevation noted on the ECG is consistent with STEMI. 22 MANAGEMENT OF ACS Several classes of medications may be used in the acute management of ACS or as part of chronic therapy to reduce the amount of myocardial tissue damage and prevent recurrent events. These may include vasodilators, such as nitrates, β blockers to reduce myocardial oxygen demand and to prevent further myocardial damage, antiplatelet agents (aspirin and clopidogrel), antithrombotics, angiotensin-converting enzyme (ACE) inhibitors, and a statin. In cases in which STEMI is present, either percutaneous coronary intervention (PCI) or administration of a thrombolytic agent is indicated. Initial therapy to reduce platelet activity may consist of aspirin and clopidogrel, which work on separate pathways of platelet aggregation. During coronary interventional procedures, a parenteral platelet glycoprotein IIb/IIIa receptor blocking agent may be used. In some situations, loading doses of clopidogrel ( mg) are used to produce a rapid onset of antiplatelet action. In some patients, a coronary artery stent (either bare-metal or drug-eluting) may be placed to keep a coronary artery open. Following stent implantation, a prolonged regimen of clopidogrel combined with aspirin is required to prevent thrombus formation within the stent. Recent observations suggest that clopidogrel (75 mg/day) in combination with aspirin may be necessary for more than 1 year after drug-eluting stent placement. 23,24 Aspirin should be continued indefinitely after this period but the optimal duration of clopidogrel administration remains uncertain. Using clopidogrel plus aspirin to prevent ACS in patients at high risk has not been shown to be superior to aspirin alone. 25 Because thrombosis plays a key role in the pathophysiology of ACS, hospitalized patients are likely to receive agents that block the effects of thrombin (heparin-related products or direct thrombin inhibitors) in addition to antiplatelet therapy. Before the introduction of low molecular weight heparin (LMWH) in the late 1980s, unfractionated heparin (UFH) was the mainstay of antithrombotic therapy, and it is still widely used in the management of ACS. LMWH does not bind as extensively to plasma and other proteins as UFH and thus, has greater bioavailability and a more predictable dose-response effect than UFH. More recently, another class of antithrombotics factor Xa inhibitors have been studied in the setting of ACS. Data from 2 large, randomized trials suggest that the introduction of these novel agents in the acute management of ACS also have clinical advantages and potential cost savings. In patients with UA or NSTE- MI, the anti-xa inhibitor fondaparinux (at the lower 2.5-mg dose) was similar to enoxaparin (1 mg/kg) in reducing the risk of ischemic events at 9 days, with an observed reduction in major bleeding and improved long-term mortality and morbidity. 26 In patients with STEMI, fondaparinux was compared to standard therapy (UFH or placebo) and reduced the risk of death or recurrent heart attack at day 30, with significant reduction as early as day In addition to antiplatelet and antithrombotic therapy, other agents, such as statins, β blockers, ACE inhibitors (or angiotensin receptor blockers), and aldosterone antagonists in selected patients, play an important role in reducing mortality and preventing recurrent events. In addition, nonpharmacologic interventions, such as exercise, behavioral changes, and smoking cessation, are additional keys to successful long-term outcomes. Use of an HMG-CoA (statin) may also be important to maintain to reduce the risk of recurrent events. 28 THE ROLE OF THE COMMUNITY PHARMACIST The most recent update to the ACC/AHA guidelines for UA/NSTEMI ACS was published in August 2007, and to the ACC/AHA STEMI-ACS guidelines in ,11 In these updates, several areas were highlighted, including: (1) earlier risk stratification at multiple time points; (2) new indications for pursuing an early invasive strategy; (3) preference for primary PCI over fibrinolytics in patients with STEMI; (4) the early use of aspirin and clopidogrel; (5) the use of glycoprotein IIb/IIIa inhibitors, especially in patients undergoing PCI or those with high-risk features; (6) initiation of an anticoagulant therapy, such as UFH, enoxaparin, fondaparinux, or bivalirudin (invasive strategy only); and (7) the early use of lipid-lowering therapy. 8,11 Therefore, it is likely that patients with ACS and/or resultant MI will return home on a variety of new medications, which may increase the likelihood of nonadherence. At present, lack of adherence to prescribed drug therapy is the most commonly reported cause of treatment failure. In several studies, only approximately 50% of patients receiving long-term treatment adequately adhered to their prescribed regimens regardless of disease state, which leads to exac- University of Tennessee Advanced Studies in Pharmacy 239
5 erbation of disease, increased mortality, and increased health costs estimated at $100 billion per year in the United States. 32,33 Poor adherence can result in recurrent ACS, morbidity, and mortality in addition to more diagnostic tests, dosage adjustments, changes in the treatment plan, emergency department visits, or hospitalization, which ultimately results in increased cost of medical care. 34 In a 6-month study assessing whether community pharmacists can impact adherence to medication, Fischer et al 35 collaborated with participants who were taking multiple medications for chronic medical conditions. Participants received initial drug therapy assessment, plan for drug therapy goals, education, interventions with other healthcare professionals if appropriate, and follow-up care. The participating patients reported receiving more information from pharmacists on all aspects of their medication, and the pharmacists were able to document improvement in compliance and patients increased awareness of potential adverse events from their medications. It is also important that community pharmacists ensure the correct continuation of prescribed medications when patients are transitioning from the inpatient or outpatient setting (ie, medication reconciliation). This can avoid additional confusion in the planned medication regimen. Therefore, it is important that the community pharmacist recognize the importance of the patients receiving and adhering to the prescribed drug therapy for the successful treatment of ACS and CHD in order to maximize patient outcomes and their quality of life. CONCLUSIONS Acute coronary syndrome is a potentially lifethreatening manifestation of coronary artery disease. The most recent updates to the ACC/AHA guidelines for NSTEMI/UA were published in The new guidelines include treatment/prophylaxis recommendations for newer anticoagulants, which may increase the likelihood of the patient s nonadherence in the outpatient setting. Poor adherence can result in recurrent ACS, as well as increases in morbidity, mortality, and overall costs of medical care. Because community pharmacists play an important role during the patient s transition from the outpatient to the inpatient setting, it is important that they be familiar with these newer agents and recognize the importance of medication adherence in the successful treatment of ACS and CHD. REFERENCES 1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e Viviott SD, Morrow DA, Giugliano RP, et al. Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction: a simple risk index predicts mortality in both ST and non-st elevation myocardial infarction. J Am Coll Cardiol. 2003;41:365A-366A. 3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104: Coronary artery disease: angina pectoris. In: Porter RS, Kaplan JL, eds. The Merck Manual. Available at: Accessed July 25, Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23: Hochman JS, Tamis JE, Thompson, TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med. 1999;341: Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from IMI IIIB. J Am Coll Cardiol. 1997;30: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:e82-e Bosanquet N, Jonsson B, Fox KAA. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Pharmacoeconomics. 2003;21: Moliterno DJ, Granger CB. Differences between unstable angina and acute myocardial infarction. In: Topol E, ed. Acute Coronary Syndromes. New York, NY: Marcel Dekker; 1998: Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116: The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335: Vol. 4, No. 9 October 2007
6 13. Califf RM. Matching resources to treatment decisions for patients with acute coronary syndromes. Clin Cardiol. 2002;25:I2-I Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J. 2006;151: Turpie A. Burden of disease: medical and economic impact of acute coronary syndromes. Am J Manag Care. 2006;12:S430-S American Heart Association and American Stroke Association. Heart Disease and Stroke Statistics 2007 Update At-a-Glance. Available at: tsinsidetext.pdf. Accessed September 20, McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: a review of the literature. J Gen Intern Med. 1990;5: Goodacre S, Locker T, Morris F, Campbell S. How useful are clinical features in the diagnosis of acute, undifferentiated chest pain? Acad Emerg Med. 2002;9: Lee TH, Cook EF, Weisberg M, et al. Acute chest pain in the emergency room. Identification and examination of lowrisk patients. Arch Intern Med. 1985;145: Cannon CP, Braunwald E. Unstable angina and non-st-elevation myocardial infraction. In: Kasper DL, Fauci AS, Longo DL, et al, eds. Harrison s Principles of Internal Medicine. 16th ed. New York, NY: Mc-Graw Hill; 2006: Yeghiazanians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med. 2000;342: Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome. Am Fam Physician. 2005;72: Spinler SA. Managing acute coronary syndrome: evidencebased approaches. Am J Health Syst Pharm. 2007; 64:S14-S Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;151: Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354: Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354: Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondarparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295: Heeschen C, Hamm CW, Laufs W, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105: Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454.e1-e Avorn J, Monette J, Lacour A, et al. Persistence of lipid-lowering medications. A cross-national study. JAMA. 1998;279: Loghman-Adham M. Medication compliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care. 2003;9: Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: O Connor P. Improving medication adherence. Arch Intern Med. 2006;166: Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43: Fischer LR, Scott LM, Boonstra DM, et al. Pharmaceutical care for patients with chronic conditions. J Am Pharm Assoc (Wash). 2000;40: University of Tennessee Advanced Studies in Pharmacy 241
Acute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationREVIEW DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK. Edith A. Nutescu, PharmD * ABSTRACT INTRODUCTION
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD * ABSTRACT Acute coronary syndrome is a form of coronary artery disease, which has a broad range of clinical presentations.
More informationAcute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC
Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57
More informationNew Guidelines for Evaluating Acute Coronary Syndrome
New Guidelines for Evaluating Acute Coronary Syndrome The American College of Cardiology and the American Heart Association [Clinician Reviews 11(1):73-86, 2001. 2001 Clinicians Publishing Group] Introduction
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationCoronary Heart Disease. Raja Nursing Instructor RN, DCHN, Post RN. BSc.N
Coronary Heart Disease Raja Nursing Instructor RN, DCHN, Post RN. BSc.N 31/03/2016 Objectives Define coronary heart disease (CHD). Identify the causes and risk factors of CHD Discuss the pathophysiological
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationOVERVIEW ACUTE CORONARY SYNDROME SYMPTOMS 9/30/14 TYPICAL WHAT IS ACUTE CORONARY SYNDROME? SYMPTOMS, IDENTIFICATION, MANAGEMENT
OVERVIEW ACUTE CORONARY SYNDROME SYMPTOMS, IDENTIFICATION, MANAGEMENT OCTOBER 7, 2014 PETE PERAUD, MD SYMPTOMS TYPICAL ATYPICAL IDENTIFICATION EKG CARDIAC BIOMARKERS STEMI VS NON-STEMI VS USA MANAGEMENT
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI
More informationDiagnosis and Management of Acute Myocardial Infarction
Diagnosis and Management of Acute Myocardial Infarction Acute Myocardial Infarction (AMI) occurs as a result of prolonged myocardial ischemia Atherosclerosis leads to endothelial rupture or erosion that
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationAnticoagulation therapy in acute coronary syndromes according to current guidelines
Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More informationPrehospital and Hospital Care of Acute Coronary Syndrome
Ischemic Heart Diseases Prehospital and Hospital Care of Acute Coronary Syndrome JMAJ 46(8): 339 346, 2003 Katsuo KANMATSUSE* and Ikuyoshi WATANABE** * Professor, Second Internal Medicine, Nihon University,
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationAwealth of research in acute coronary syndrome
CLINICAL TRIAL SUPPORT OF THE USE OF CRITICAL PATHWAYS IN IMPROVING PATIENT OUTCOMES Judy W. M. Cheng, PharmD, MPH, BCPS, FCCP * ABSTRACT Acute coronary syndrome (ACS) is a common condition encountered
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Vorapaxar for the secondary prevention of atherothrombotic events after myocardial infarction Draft scope (pre-referral)
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationTYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016
TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding
More informationGuidelines and Performance Measures for the Management of Acute Coronary Syndrome
Guidelines and Performance Measures for the Management of Acute Coronary Syndrome Piotr Sobieszczyk, MD ABSTRACT BACKGROUND: Acute coronary syndrome (ACS) is caused by reduced perfusion of the myocardium
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationManaging Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics
Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics Robert L. Jesse, MD, PhD National Program Director for Cardiology Veterans Health Administration Washington, DC Chief, Cardiology
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationResults of Ischemic Heart Disease
Ischemic Heart Disease: Angina and Myocardial Infarction Ischemic heart disease; syndromes causing an imbalance between myocardial oxygen demand and supply (inadequate myocardial blood flow) related to
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationObjectives. Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2
10/2013 1 Objectives Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2 Purpose of this Education Module: Chest Pain Center Accreditation involves
More information2010 ACLS Guidelines. Primary goals of therapy for patients
2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in
More informationIschemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland
Ischemic and bleeding risk stratification in NSTE ACS Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Disclosure Andrzej Budaj, MD, PhD, reports the following potential conflicts
More informationAntiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital
Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationGuide to GRACE manuscripts (1999 to 2006)
Guide to GRACE manuscripts (1999 to 2006) # Topic Year of publication (enrollment period) Patient group N Summary Reference 1. Overview: study design 2001 All ACS Aim: To explain the rationale behind GRACE
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationAcute Coronary Syndrome. Emergency Department Updated Jan. 2017
Acute Coronary Syndrome Emergency Department Updated Jan. 2017 Goals and Objectives To reduce mortality and morbidity for people who have cardiovascular disease, with a focus on those who experience an
More informationCindy Stephens, MSN, ANP Kelly Walker, MS, ACNP Peter Cohn, MD, FACC
Cindy Stephens, MSN, ANP Kelly Walker, MS, ACNP Peter Cohn, MD, FACC Define Acute Coronary syndromes Explain the Cause Assessment, diagnosis and therapy Reperfusion for STEMI Complications to look for
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationCardiovascular Concerns in Intermediate Care
Cardiovascular Concerns in Intermediate Care GINA ST. JEAN RN, MSN, CCRN-CSC CLINICAL NURSE EDUCATOR HEART AND & CRITICAL AND INTERMEDIATE CARE Objectives: Identify how to do a thorough assessment of the
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationAcute Coronary Syndromes: Selective vs Early Invasive Strategies
Acute Coronary Syndromes: Selective vs Early Invasive Strategies WilliamE.Boden,MD,FACCandVipulGupta,MBBS,MPH Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health,
More informationAcute Coronary Syndromes: Review and Update
Acute Coronary Syndromes: Review and Update Core Curriculum for the Cardiovascular Clinician September 14-17, 2016 R. David Anderson, MD, MS, FACC Professor of Medicine Director of Interventional Cardiology
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationAIMS: CHEST PAIN. Causes of chest pain. Causes of chest pain: Cardiac causes: Acute coronary syndromes pericarditis thoracic aortic dissection
CHEST PAIN Dr Susan Hertzberg Emergency Department Prince of Wales Hospital AIMS: To identify causes of chest pain in patients presenting to the ED. To identify and risk stratify patients presenting with
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 DUOPLAVIN 75 mg/75 mg, film-coated tablet B/30 (CIP code: 359 022-6) B/30 (CIP code: 382 063-7) DUOPLAVIN
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02963-7
More informationOP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records.
Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Chest Pain (CP) Set Measure ID # OP-4 * OP-5 * Measure Short Name Aspirin at Arrival
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationHeart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United
Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United States, totaling about 750,000 individuals annually
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationMore than 1 million percutaneous coronary intervention
n report n Percutaneous Coronary Intervention: Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology) Abstract Percutaneous
More informationEarly Management of Acute Coronary Syndrome
Early Management of Acute Coronary Syndrome Connie Hess, MD, MHS University of Colorado Division of Cardiology Acute Coronary Syndrome (ACS) A range of conditions associated with sudden imbalance in myocardial
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationChest pain affects 20% to 40% of the general population during their lifetime.
Chest pain affects 20% to 40% of the general population during their lifetime. More than 5% of visits in the emergency department, and up to 40% of admissions are because of chest pain. Chest pain is a
More informationChest Pain Accreditation ACS Education
Chest Pain Accreditation ACS Education Objectives Recognize the Typical and Atypical Signs and Symptoms of ACS Recognize Gender and Age Differences of ACS Recognize the Risk Factors of ACS Understand Early
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationAcute Coronary Syndrome (ACS) Initial Evaluation and Management
Acute Coronary Syndrome (ACS) Initial Evaluation and Management Symptoms of Possible ACS Chest discomfort with or without radiation to the arm(s), jaw, or epigastrium Short of breath Weakness Diaphoresis
More informationLife Science Journal 2016;13(5) Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study
Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study Samim Emet, MD 1, Fatih Akdogan 2, Yucel Arman 2, Murat Kose, MD 3, Basak Saracoglu, MD 4, Tufan Tukek, MD 3 1 Istanbul
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationAcute Coronary Syndrome: Management of the patients with Unstable Angina and Non-ST Segment Elevation Myocardial Infarction Rahman S, Rahman KA
Acute Coronary Syndrome: Management of the patients with Unstable Angina and Non-ST Segment Elevation Myocardial Infarction Rahman S, Rahman KA Introduction Acute Coronary Syndrome (ACS) kills and disables
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Acute Myocardial Infarction (AMI) Set Measure ID#: Performance Measure Name:
More information